The -opioid receptor gene undergoes extensive alternative splicing to generate an array of splice variants. One group of splice variants excludes the first transmembrane (TM) domain and contains six TM domains. These 6TM variants are essential for the action of a novel class of analgesic drugs, including 3-iodobenzoyl-6-naltrexamide, which is potent against a spectrum of pain models without exhibiting the adverse side effects of traditional opiates. The 6TM variants are also involved in analgesic action through other drug classes, including -opioid and opioids and -adrenergic drugs. Of the five 6TM variants in mouse, mouse -opioid receptor (mMOR)-1G is abundant and conserved from rodent to human. In the present study, we demonstrate a new function of mMOR-1G in enhancing expression of the full-length 7TM -opioid receptor, mMOR-1. When coexpressed with mMOR-1 in a Tet-Off inducible CHO cell line, mMOR-1G has no effect on mMOR-1 mRNA expression but greatly increases mMOR-1 protein expression in a dose-dependent manner determined by opioid receptor binding and [S] guanosine 5'-3--(thio)triphosphate binding. Subcellular fractionation analysis using OptiPrep density gradient centrifugation shows an increase of functional mMOR-1 receptor in plasma membrane-enriched fractions. Using a coimmunoprecipitation approach, we further demonstrate that mMOR-1G physically associates with mMOR-1 starting at the endoplasmic reticulum, suggesting a chaperone-like function. These data provide a molecular mechanism for how mMOR-1G regulates expression and function of the full-length 7TM -opioid receptor. SIGNIFICANCE STATEMENT: The current study establishes a novel function of mouse -opioid receptor (mMOR)-1G, a truncated splice variant with six transmembrane (TM) domains of the mouse -opioid receptor gene, in enhancing expression of the full-length 7TM mMOR-1 through a chaperone-like function.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7562973PMC
http://dx.doi.org/10.1124/mol.120.119453DOI Listing

Publication Analysis

Top Keywords

-opioid receptor
24
expression full-length
12
6tm variants
12
mouse -opioid
12
full-length 7tm
12
receptor
9
splice variant
8
opioid receptor
8
receptor gene
8
splice variants
8

Similar Publications

Developing Topics.

Alzheimers Dement

December 2024

Cognition Therapeutics, Inc, Pittsburgh, PA, USA.

Background: The sigma-2 receptor (S2R) modulator CT1812 is a first-in-class investigational therapeutic, currently in Phase 2 clinical trials for Alzheimer's disease (AD). Preclinical and clinical studies have shown that CT1812 displaces Aβ oligomers from synapses and clears them from the brain into the cerebrospinal fluid, restoring cognitive performance in a transgenic mouse model of AD. To investigate the mechanism of action of CT1812 and enable biomarker discovery, a phosphoproteomic analysis of CSF samples from SHINE-A was performed.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

Cognition Therapeutics, Inc, Pittsburgh, PA, USA.

Background: A Phase 2 randomized, double-blind, placebo-controlled 6-month trial, SHINE (NCT03507790), was designed to include up to 144 participants with mild to moderate Alzheimer's disease (AD) to study the effects of the sigma-2 receptor (S2R) modulator CT1812 on cognition, safety, and biomarkers. CSF canonical and exploratory biomarkers were assessed to determine treatment effects with CT1812.

Method: Participants (n = 153) received a daily oral dose of either CT1812 (100 mg or 300 mg) or placebo during the treatment period of 6-months.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

Cognition Therapeutics, Inc, Pittsburgh, PA, USA.

Background: SHINE (NCT03507790, COG0201) is a Phase 2 randomized, double-blind, placebo-controlled 6-month trial, conducted to study the effect of the sigma-2 receptor (S2R) modulator CT1812 in patients with Alzheimer's disease (AD). An unbiased assessment of CSF proteomes from the patients that completed the SHINE trial was performed to identify pharmacodynamic (PD) biomarkers of target/pathway engagement and disease modification for CT1812.

Method: Tandem-mass tag mass spectrometry (TMT-MS) CSF proteomics was performed on baseline and end of study samples from an analysis of SHINE Part A and B to test the effects of two doses (100 mg, 300 mg; given orally, once daily) of CT1812 compared to placebo in mild to moderate AD patients.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Cognition Therapeutics, Purchase, NY, USA.

Background: CT1812 is an experimental therapeutic sigma-2 receptor modulator in development for Alzheimer's disease (AD) and dementia with Lewy bodies. CT1812 reduces the affinity of Aβ oligomers to bind to neurons and exert synaptotoxic effects. This phase 2, multi-center, international, randomized, double-blind, placebo-controlled trial assessed safety, tolerability and effects of CT1812 on cognitive function in individuals with AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Axsome Therapeutics, New York, NY, USA.

Background: Patients with Alzheimer's disease (AD) often experience burdensome neuropsychiatric symptoms, including agitation which occurs in both home and long-term care (LTC) facilities, and is associated with substantial increases in caregiver burden and LTC placements. AXS-05 (45-mg dextromethorphan/105-mg bupropion), a novel, oral NMDA receptor antagonist and sigma-1 receptor agonist, approved by the FDA for major depressive disorder, is being investigated for treatment of AD agitation (ADA). AXS-05 has been evaluated in 2 randomized, double-blind studies: Phase 2 ADVANCE-1 (NCT03226522); Phase 3 ACCORD (NCT04797715).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!